When: Pullback to $230-240 zone (200 SMA + modest margin) with structural level holding

Then: Re-engage at one-third of trimmed size

HOLD

• JNJ ran 60 percent over twelve months on defensive characteristics, 64-year dividend streak, and post-Kenvue transformation—not momentum trading
• Beta of 0.231 indicates institutional accumulation tied to bond-proxy characteristics, not speculative momentum
• MACD rollover is explicitly described in the technical report as "a short-term momentum wobble within an intact uptrend, not a trend break"
• RSI at 56.8 is neutral-bullish
• Price failing at 266.73 is first test of meaningful resistance after 60 percent run, not a double top
• 30-year Treasury at 4.7 to 5.0 percent represents duration risk—if inflation re-accelerates, bond loses 15 to 20 percent principal as yields push toward 5.5 or 6 percent
• Forward EPS implies 43 percent growth from TTM as litigation charges normalize, M&A pipeline matures, and biosimilar drag continues to shrink
• Median forward P/E for large-cap pharma in low-recession-probability environment is 19 to 22 times, not the 18-times compression target cited by Aggressive Analyst
• Balance sheet has absorbed M&A wave with manageable leverage at 57 percent debt-to-equity
• ROE at 25.7 percent
• Dividend grew 3.1 percent on record quarterly results
• Maintain stop at 200-day SMA around 228—structural floor aligning with Trader's stop placement
• Reassess only if price breaks 50-day SMA at 251 with volume confirming distribution

→ vs aggressive: 40 to 50 percent trim is reckless—fundamental thesis is not broken; thesis requires fundamental break, not technical wobble within intact uptrend

→ vs aggressive: Treasury rotation argument is flawed—30-year bond has duration risk and negative convexity in sticky-rates regime, not risk-free; swapping low-volatility equity with dividend growth and buybacks for a bond at 19-year high yields is transmuting one risk into another

→ vs aggressive: Asymmetric trade (40 dollars downside to 15 to 20 dollars upside) is asserted, not supported; forward EPS implies 43 percent growth normalization

→ vs aggressive: 18-times multiple compression target is a counterfactual pulled from nowhere when sector median is 19 to 22 times

→ vs aggressive: Selling into strength is market timing—the entire reason this stock is in the portfolio is because it doesn't behave like a name you need to trade around

→ vs neutral: Trader's sell thesis and Aggressive Analyst's trim are impulse-driven decisions that destroy patient capital

HOLD

• Forward P/E above 21 and PEG above 4.5 indicate elevated valuation creating asymmetry risk
• MACD rollover after failed test at 266.73 signals easy momentum has shifted
• 20-30% trim into 260-266 zone is the calibrated response—not 40-50% (aggressive) or 0% (conservative)
• Core position of 60-70% should be retained; fundamental thesis not broken: revenue mid-single digits, FCF expanding 4th consecutive year, ROE at 25.7%, dividend grew
• M&A pipeline from 32.7 billion deployed over 2024-2025 needs time to mature; selling everything abandons compounding
• Redeploy trimmed capital into intermediate Treasuries (3-5 year duration) and cash buffer rather than long-duration Treasuries
• Stop placement at 228 aligns with 200 SMA—level at which secular trend would be in jeopardy
• Cash buffer preserves dry powder for reload if JNJ pulls back to 50 SMA at 251 or 200 SMA at 228
• 30-year Treasury at 4.7-5% creates genuine opportunity cost against 2% dividend yield but carries duration risk
• Aggressive analyst's 18x earnings compression target is a counterfactual; JNJ trades at 19-22x, not 18x

→ vs aggressive: 30-year Treasury at 19-year high is not risk-free—maximum duration risk at 4.7-5% with sticky inflation creates two-way rate risk; if yields hit 5.5-6%, buyer faces 15-20% mark-to-market loss

→ vs aggressive: The implied 18x forward earnings compression target is a counterfactual pulled from nowhere; large-cap pharma in defensive rotation with low recession probability trades at 19-22x, not 18x

→ vs aggressive: 40-50% trim overreach—the asymmetry is narrower than advertised when base case valuation is 19-22x, not 18x

→ vs conservative: MACD rollover with negative histogram is not noise—it is a legitimate reason to acknowledge that easy momentum has shifted, even if not a reason to panic

→ vs conservative: Opportunity cost argument is legitimate: holding 2% dividend yield while 30-year Treasury offers 4.7-5% is a real economic choice

→ vs conservative: Do-nothing stance until 50 SMA breaks is reactive, not proactive, and accepts 10-15% drawdown before taking action

→ vs conservative: Disciplined trimming after substantial rally is risk management, not market timing heresy